Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M775Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M21.1EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)18.7Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.610-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %3.8PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M51,750,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PID

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

PID is held by these investors:



PID: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.4858.02view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94-11.57view
DINWOODIE, TYLER WAYNE PAULSenior Officer 2017-01-16Buy4,000$0.178711.76view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.361001.47view
Bebek, IvanDirector 2017-01-16Buy8,990$3.38343.2view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.413553.66view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91-46.33view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.27138.92view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.38-75.19view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.159886.67view

Quarterly/Annual Reports about PID:

    News about PID:

    Articles On GuruFocus.com
    Searching The World For The Best Dividend Stocks Jan 06 2015 

    More From Other Websites
    This Keeps Driving Sanofi’s Growth Feb 20 2017
    GlaxoSmithKline’s Consumer Healthcare Reports Growth in 4Q16 Feb 16 2017
    GlaxoSmithKline’s Vaccines Business Reported Growth in 4Q16 Feb 15 2017
    4Q16 Performance of GlaxoSmithKline’s Business Segments Feb 14 2017
    Novartis’s Innovative Medicines Segment in 4Q16 Feb 01 2017
    PotashCorp in 4Q16: Nitrogen Prices Added Salt to the Wound Jan 30 2017
    Novartis’s 4Q16 Estimates: Innovative Medicines Segment Jan 23 2017
    How Did Novartis’s Generics Business Perform in 3Q16? Jan 17 2017
    How GlaxoSmithKline’s Pharmaceuticals Segment Has Performed Dec 30 2016
    4 High Dividend ETFs Under $20 Dec 13 2016
    PowerShares Announces Listing Transfer for 27 ETFs Nov 23 2016
    How Sandoz Performed for Novartis in 3Q16 Nov 17 2016
    How Tresiba Helps Novo Achieve Its Growth Targets Nov 03 2016
    Victoza Dominates Global GLP-1 Class Nov 03 2016
    Reading Novo’s Insulin Portfolio to Find Clues about Its Growth Nov 02 2016
    US Still the Largest Market for Novo Nordisk Nov 01 2016
    Why Did PotashCorp’s Nitrogen Prices Fall in 3Q16? Nov 01 2016
    How Much Is the Return Opportunity for Novo Nordisk in 3Q16? Oct 25 2016
    Novartis’s 3Q16 Estimates: Will Alcon Recover Its Growth? Oct 24 2016
    Novartis’s 3Q16 Estimates: Innovative Medicines Segment Oct 24 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)